Chembio Diagnostics, Inc. (NASDAQ: CEMI) is committed to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). At the core of its commitment is its patented Next Generation DPP (Dual Path Platform) … Continue reading →

Bionik Laboratories Corp. (OTC: BNKL), a medical device and robotics company, focuses on robotic exoskeleton technology for those with mobility impairments. The technology gives users a chance to rehabilitate effectively by being able to walk. Bionik Laboratories has researched, developed … Continue reading →

Asterias Biotherapeutics, Inc. (NYSE: AST) is engaged in the emerging field of regenerative medicine. The company’s proprietary platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias’ portfolio includes: AST-OPC1, currently in a phase I/IIa dose … Continue reading →

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases with clear unmet needs. The company’s lead product candidate, Resunab, is a first-in-class, synthetic oral endocannabinoid-mimetic drug that targets … Continue reading →

Arch Therapeutics (NASDAQ: ARTH), a medical device company, offers an innovative approach to rapid cessation of bleeding and control of fluid during surgery and trauma care. The underlying technology, exclusively licensed from a leading university, supports an innovative platform of … Continue reading →

Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical focused on the development and commercialization of therapeutics for the treatment of liver diseases. The company is developing Aramchol, which is in phase 2b clinical trial for the treatment of non-alcoholic steato-hepatitis … Continue reading →

ContraFect Corp. (NASDAQ: CFRX) is a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. The company is finding answers to drug-resistant and newly-emerging pathogens that are responsible for hospital-based … Continue reading →

Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine company principally engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. The company is focused on developing and marketing safe and effective cell-based therapies based … Continue reading →

Sevion Therapeutics, Inc. (OTC: SVON) discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. Sevion’s … Continue reading →